Despite the move towards NOACs for the prevention of thromboembolic disease, transition is not smooth for some patients and about 5% will revert back to warfarin. This is the conclusion of a Queensland study of more than 3,000 patients in a warfarin program, which found 4.7% of patients switched back from NOACs, typically within six ...
Switching to NOACs doesn’t suit all
By Mardi Chapman
15 Aug 2018